Liquisolid Compacts: A Paradigm in Drug Delivery System

Liquisolid compacts (LSCs) are a fascinating drug delivery technology that offers numerous advantages, particularly for Biopharmaceutical Classification System (BCS) class 2 drugs. In essence, they convert liquid medications into free-flowing, compressible powder forms suitable for tablet production with improved drug release characteristics. Formulation of liquisolid compacts represents a valuable strategy in overcoming solubility challenges, ultimately contributing to the development of effective and patient-friendly drug delivery system. This paper reviews the key components and the formulation process involved in developing liquisolid compacts. The improved wettability of the drug and the increased surface area of the molecularly dispersed drug in the liquid environment contribute to enhanced solubility. Pre- and post-compression tests are performed to optimize liquisolid compacts. Solid-state characterization studies (FTIR, DSC, SEM, PXRD) ensure drug-excipient compatibility. Accelerated stability studies demonstrate the safety and stability of liquisolid formulations over time. Thus, exploring different techniques and excipients can boost the pharmaceutical industry in designing stable and efficacious liquisolid compacts.